Denali Therapeutics (NASDAQ:DNLI) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report released on Friday, MarketBeat.com reports. The brokerage issued an overweight rating and a $35.00 price target on the stock.

DNLI has been the topic of a number of other research reports. Wedbush raised their target price on shares of Denali Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, November 4th. Morgan Stanley increased their price target on Denali Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Denali Therapeutics in a report on Wednesday, November 4th. Deutsche Bank boosted their price objective on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Denali Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $35.71.

Check Out Our Latest Report on Denali Therapeutics

Denali Therapeutics Stock Performance

DNLI opened at $18.74 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.21 and a quick ratio of 5.94. Denali Therapeutics has a 12-month low of $15.34 and a 12-month high of $27.30. The firm’s fifty day moving average price is $19.77 and its 200 day moving average price is $21.25. The stock has a market capitalization of $3.00 billion, a PE ratio of -10.83 and a beta of 1.08.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.64. The firm had revenue of $17.78 million during the quarter, compared to the consensus estimate of $12.67 million. During the same period in the prior year, the firm earned ($0.74) earnings per share. As a group, research analysts expect that Denali Therapeutics will post -2.62 EPS for the current fiscal year.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,768 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total value of $64,881.92. Following the completion of the sale, the insider directly owned 278,995 shares of the company’s stock, valued at approximately $6,539,642.80. This represents a 0.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.70% of the company’s stock.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNLI. Jump Financial LLC acquired a new position in Denali Therapeutics in the third quarter worth approximately $567,000. Marshall Wace LLP boosted its stake in shares of Denali Therapeutics by 46.1% during the 3rd quarter. Marshall Wace LLP now owns 803,420 shares of the company’s stock worth $16,607,000 after acquiring an additional 253,590 shares in the last quarter. Global Retirement Partners LLC grew its holdings in shares of Denali Therapeutics by 65.9% in the 3rd quarter. Global Retirement Partners LLC now owns 1,830 shares of the company’s stock worth $38,000 after acquiring an additional 727 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of Denali Therapeutics by 13.0% in the 3rd quarter. Aberdeen Group plc now owns 1,520,605 shares of the company’s stock worth $31,431,000 after acquiring an additional 175,124 shares during the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Denali Therapeutics by 1.9% in the 3rd quarter. Fisher Asset Management LLC now owns 2,460,545 shares of the company’s stock worth $50,859,000 after acquiring an additional 46,383 shares during the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

(Get Free Report)

Denali Therapeutics is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California. Its research and development programs target conditions including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali’s portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier.

Further Reading

Analyst Recommendations for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.